Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Ferguson

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
BMJ (Clinical Research Ed.)|March 9, 2002
From patients to end usersTom Ferguson
BMJ (Clinical Research Ed.)|May 15, 2004
The first generation of e-patientsTom Ferguson, Gilles Frydman
Plos Medicine|August 3, 2005
What I've learned from E-patientsDan Hoch, Tom Ferguson
Therapeutic Advances in Medical Oncology|July 27, 2011
Which patients with renal cancer may benefit from sunitinib therapy?Tom Ferguson, Martin Gore
European Journal of Nuclear Medicine and Molecular Imaging|April 20, 2026
Longitudinal renal function following [¹⁷⁷Lu]Lu-PSMA I&T in metastatic castration-resistant prostate cancerMatthew Cockcroft, Tom Ferguson, Katie Meehan, et al.
Journal of General Internal Medicine|July 30, 2005
Brief report: What types of Internet guidance do patients want from their physicians?Joseph A Diaz, Christophern N Sciamanna, Evangelos Evangelou, et al.
BJU International|May 7, 2021
A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocolAndrew Moe, Elizabeth Liow, Andrew Redfern, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 18, 2026
Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia studyClaudia Leslie, Zeyad Al-Ogaili, Leone Oh, et al.
BMJ Open|April 16, 2022
<sup>89</sup>Zirconium-labelled girentuximab (<sup>89</sup>Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinomaMohammed Al-Zubaidi, Pravin Viswambaram, Steve McCombie, et al.
BMJ Open|June 1, 2017
Can exercise suppress tumour growth in advanced prostate cancer patients with sclerotic bone metastases? A randomised, controlled study protocol examining feasibility, safety and efficacyNicolas H Hart, Robert U Newton, Nigel A Spry, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
BMJ (Clinical Research Ed.)|March 9, 2002
From patients to end usersTom Ferguson
BMJ (Clinical Research Ed.)|May 15, 2004
The first generation of e-patientsTom Ferguson, Gilles Frydman
Plos Medicine|August 3, 2005
What I've learned from E-patientsDan Hoch, Tom Ferguson
Therapeutic Advances in Medical Oncology|July 27, 2011
Which patients with renal cancer may benefit from sunitinib therapy?Tom Ferguson, Martin Gore
European Journal of Nuclear Medicine and Molecular Imaging|April 20, 2026
Longitudinal renal function following [¹⁷⁷Lu]Lu-PSMA I&T in metastatic castration-resistant prostate cancerMatthew Cockcroft, Tom Ferguson, Katie Meehan, et al.
Journal of General Internal Medicine|July 30, 2005
Brief report: What types of Internet guidance do patients want from their physicians?Joseph A Diaz, Christophern N Sciamanna, Evangelos Evangelou, et al.
BJU International|May 7, 2021
A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocolAndrew Moe, Elizabeth Liow, Andrew Redfern, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 18, 2026
Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia studyClaudia Leslie, Zeyad Al-Ogaili, Leone Oh, et al.
BMJ Open|April 16, 2022
<sup>89</sup>Zirconium-labelled girentuximab (<sup>89</sup>Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinomaMohammed Al-Zubaidi, Pravin Viswambaram, Steve McCombie, et al.
BMJ Open|June 1, 2017
Can exercise suppress tumour growth in advanced prostate cancer patients with sclerotic bone metastases? A randomised, controlled study protocol examining feasibility, safety and efficacyNicolas H Hart, Robert U Newton, Nigel A Spry, et al.
Pageof 2